5 terminated, 3 completed, 3 recruiting, 1 active not recruiting. 11 Phase 3, 1 Phase 1, 1 Phase 2.
By phase and status
Follow Kodiak Sciences Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
Tabirafusp tedromer, Aflibercept (2.0 mg) - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | Kodiak Sciences Inc | 910 | 2026-08-03 | 2026-08-21 |
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
KSI-101, Sham Comparator - Macular Edema Secondary to Inflammation | Phase 3 | Recruiting | Kodiak Sciences Inc | 600 | 2025-07-30 | 2026-05-18 |
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
KSI-101, Sham Comparator - Macular Edema Secondary to Inflammation | Phase 3 | Recruiting | Kodiak Sciences Inc | 300 | 2025-07-16 | 2026-05-18 |
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept - Wet Age-related Macular Degeneration | Phase 3 | Active not recruiting | Kodiak Sciences Inc | 675 | 2024-08-23 | 2026-04-29 |
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
Tarcocimab, Sham injection - Diabetic Retinopathy | Phase 3 | Completed | Kodiak Sciences Inc | 255 | 2024-05-01 | 2026-05-13 |
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
KSI-301, Sham injection - Non-proliferative Diabetic Retinopathy | Phase 3 | Terminated | Kodiak Sciences Inc | 253 | 2021-09-07 | 2024-09-05 |
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
KSI-301, Aflibercept, Sham Procedure - Wet Age-related Macular Degeneration | Phase 3 | Completed | Kodiak Sciences Inc | 557 | 2021-06-23 | 2024-07-03 |
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
KSI-301, Aflibercept, Sham Procedure - Diabetic Macular Edema | Phase 3 | Terminated | Kodiak Sciences Inc | 459 | 2020-09-30 | 2024-08-22 |
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
KSI-301, Aflibercept, Sham Procedure - Diabetic Macular Edema | Phase 3 | Terminated | Kodiak Sciences Inc | 460 | 2020-09-30 | 2024-08-22 |
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
KSI-301, Aflibercept, Sham Procedure - Macular Edema, Retinal Vein Occlusion | Phase 3 | Completed | Kodiak Sciences Inc | 568 | 2020-09-25 | 2024-06-26 |
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
KSI-301, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 2 / Phase 3 | Terminated | Kodiak Sciences Inc | 559 | 2019-10-08 | 2024-07-18 |
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
KSI-301 - Wet Age-related Macular Degeneration, Retinal Vein Occlusion | Phase 1 | Terminated | Kodiak Sciences Inc | 121 | 2018-12-26 | 2024-03-20 |
Conditions studied
Eye Diseases (7) · Retinal Degeneration (7) · Retinal Diseases (7) · Vision Disorders (7) · Macular Edema (5) · Vision, Low (5) · Diabetic Retinopathy (4) · Diabetes Mellitus (2) · Macular Degeneration (2) · Retinal Vein Occlusion (2) · Wet Macular Degeneration (1)
Interventions
aflibercept (7) · salicylhydroxamic acid (2)
Countries
United States (12) · Puerto Rico (9) · Czechia (4) · Latvia (4) · Poland (4) · Slovakia (4) · Spain (4) · Germany (3) · Hungary (3) · Italy (3) · France (2) · Israel (2)
Top investigators
Pablo Velazquez-Martin, MD (10) · Daniel Janer, MD (1) · J. Pablo Velazquez-Martin, MD (1)
Results publications
PMID 42054088